TY - JOUR
T1 - Efficacy of combined transarterial radioembolization and sorafenib in the treatment of hepatocarcinoma
T2 - A meta-analysis
AU - Facciorusso, Antonio
AU - Paolillo, Rosa
AU - Tartaglia, Nicola
AU - Ramai, Daryl
AU - Mohan, Babu P.
AU - Cotsoglou, Christian
AU - Chandan, Saurabh
AU - Ambrosi, Antonio
AU - Bargellini, Irene
AU - Renzulli, Matteo
AU - Sacco, Rodolfo
N1 - Funding Information:
Study design: Antonio Facciorusso. Data collection: Antonio Facciorusso, Nicola Tartaglia, Rosa Paolillo, Daryl Ramai, Babu P Mohan, Christian Cotsoglou, Saurabh Chandan, Antonio Ambrosi, Irene Bargellini. Data analysis: Antonio Facciorusso. Draft writing: Antonio Facciorusso, Rodolfo Sacco, Matteo Renzulli. All the authors approved the final manuscript. None. The authors have no conflicts of interest to declare.
Publisher Copyright:
© 2021
PY - 2022/3
Y1 - 2022/3
N2 - Background: Adjuvant sorafenib may further enhance the efficacy of transarterial radioembolization for the treatment of hepatocellular carcinoma. Aims: To evaluate the efficacy and safety of radioembolization plus sorafenib in hepatocellular carcinoma patients. Methods: With a literature search through October 2020, we identified 9 studies (632 patients). Primary outcome was overall survival. Results were expressed as pooled median, odds ratio, or hazard ratio and 95% confidence intervals. Results: Pooled overall survival after radioembolization plus sorafenib was 10.79 months (95% confidence interval 9.19–12.39) and it was longer in Barcelona Clinic Liver Cancer (BCLC) B (14.47 months, 9.07–19.86) as compared to BCLC C patients (10.22 months, 7.53–12.9). No difference between combined therapy versus radioembolization alone was observed in terms of overall survival (hazard ratio 1.07, 0.89–1.30). Pooled median progression-free survival was 6.32 months (5.68–6.98), with 1-year progression-free survival pooled rate of 38.5% (12.7%-44.2%). No difference in progression-free survival (hazard ratio 0.94, 0.79–1.12) between the two treatments was observed. Pooled rate of severe adverse events was 48.9% (26.7%-71.2%), again with no difference between the two treatment regimens (odds ratio 1.52, 0.15–15.02). Conclusions: The association of sorafenib does not seem to prolong survival nor delay disease progression in patients treated with radioembolization.
AB - Background: Adjuvant sorafenib may further enhance the efficacy of transarterial radioembolization for the treatment of hepatocellular carcinoma. Aims: To evaluate the efficacy and safety of radioembolization plus sorafenib in hepatocellular carcinoma patients. Methods: With a literature search through October 2020, we identified 9 studies (632 patients). Primary outcome was overall survival. Results were expressed as pooled median, odds ratio, or hazard ratio and 95% confidence intervals. Results: Pooled overall survival after radioembolization plus sorafenib was 10.79 months (95% confidence interval 9.19–12.39) and it was longer in Barcelona Clinic Liver Cancer (BCLC) B (14.47 months, 9.07–19.86) as compared to BCLC C patients (10.22 months, 7.53–12.9). No difference between combined therapy versus radioembolization alone was observed in terms of overall survival (hazard ratio 1.07, 0.89–1.30). Pooled median progression-free survival was 6.32 months (5.68–6.98), with 1-year progression-free survival pooled rate of 38.5% (12.7%-44.2%). No difference in progression-free survival (hazard ratio 0.94, 0.79–1.12) between the two treatments was observed. Pooled rate of severe adverse events was 48.9% (26.7%-71.2%), again with no difference between the two treatment regimens (odds ratio 1.52, 0.15–15.02). Conclusions: The association of sorafenib does not seem to prolong survival nor delay disease progression in patients treated with radioembolization.
UR - http://www.scopus.com/inward/record.url?scp=85108964148&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85108964148&partnerID=8YFLogxK
U2 - 10.1016/j.dld.2021.06.003
DO - 10.1016/j.dld.2021.06.003
M3 - Review article
C2 - 34193367
AN - SCOPUS:85108964148
VL - 54
SP - 316
EP - 323
JO - Digestive and Liver Disease
JF - Digestive and Liver Disease
SN - 1590-8658
IS - 3
ER -